Evaluating the safety and efficacy of the Adult PCV13 Vaccine

Our study, published in Expert Review of Vaccines, set out to establish clinical best practices and optimise adult immunisation strategies.

The Clinical Gap: Despite indirect protection from childhood immunisations and the use of older non-conjugated vaccines, pneumococcal disease remains a major, life-threatening danger to adults.

The Outcome: Through a comprehensive narrative review of the clinical literature, this project demonstrated that PCV13 is highly safe and triggers a significantly stronger immune response than older vaccines. Crucially, it established that administering PCV13 first primes the immune system for optimal, long-term protection against severe pneumonia and invasive infections.

The Impact: These findings delivered top-tier clinical impact. They were rapidly integrated into official, government-recognised medical guidelines within two years of publication, serving as a key evidence source in the National Immunisation Programme in the Netherlands.

We've summarised the key takeaway message below.

To bring this narrative review to life and establish clear clinical guidance on adult pneumococcal immunisation, Momentum Data provided end-to-end project support.

The findings were so critical that they were rapidly integrated into official, government-recognised medical guidelines within two years of publication.

They now serve as a key evidence source in the National Immunisation Programme in the Netherlands to inform clinical policy.

Our core contributions included:

  • Study Conception: Project conceptualisation and methodology

  • Narrative Review: Comprehensive review of the literature

  • Data Visualisation: Clear presentation of complex clinical findings

  • Medical Writing: Complete manuscript development

  • Publication Support: Targeted submission and review follow-up

Read the full paper here

NEW

PUBLICATION

Turning real world data into impactful evidence

Ultimately, our goal is simple:
To produce dynamic, engaging outputs that truly tell the story of the evidence - and make sure it’s heard.

Previous
Previous

Atopic Dermatitis - understanding the risk of autoimmune conditions